1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Seagen, Astellas Data Support Broader Indication For Padcev/Keytruda Combo

Data May Facilitate Closing Of Pfizer Merger

 
• By Joseph Haas

With accelerated approval in advanced urothelial cancer, the sponsors now have data that could support full approval.

Antibody-drug conjugate
Seagen/Astellas's Padcev might now be appropriate treatment in more bladder cancer patients • Source: Shutterstock

Seagen Inc. and Astellas Pharma, Inc.’s antibody-drug conjugate Padcev met both overall and progression-free survival endpoints in a top-line readout from the Phase III EV-302/KEYNOTE-A39 trial testing the ADC in combination with Merck & Co., Inc.’s anti-PD-1 stalwart Keytruda, results that analysts said could increase Padcev’s addressable market in urothelial cancer to the $5bn range and de-risk the expected close of Seagen’s merger with Pfizer Inc.

Although the companies did not provide numerical data, saying full details will be disclosed at an upcoming medical conference, the...

Welcome to Scrip

Create an account to read this article

Already a subscriber?

More from Clinical Trials

AstraZeneca Faces Close Race With Mineralys After Phase III Hypertension Readout

 
• By Andrew McConaghie

There is little to divide the Phase III results for the two aldosterone synthase inhibitors, though AstraZeneca’s combination and cardiovascular outcomes studies could bear fruit in the long-term.

BeOne Preps For Sonrotoclax MCL Filing, With Sights Set On AbbVie/Roche’s Territory

 
• By Alaric DeArment

The biotech announced positive topline Phase I/II results for the BCL2 inhibitor in late-line mantle cell lymphoma, with Phase III studies underway in chronic lymphocytic leukemia.

J&J Keeps Faith In Nipocalimab’s $5bn Sales Target Despite RA Trial Setback

 
• By Manas Mishra

Johnson & Johnson will push ahead with its 'pipeline-in-a-product' plans for Imaavy despite pulling the plug on its development in rheumatoid arthritis.

DualityBio Eyes 1L Use For ADC Combos With BioNTech’s Bispecific

 
• By Dexter Jie Yan

Duality is fast-tracking the development of three of its ADC candidates in combination with partner BioNTech's BNT327, an anti-PD-L1/VEGF-A bispecific antibody, in four studies, with certain cohorts evaluating first-line use in various cancers.

More from R&D

Lilly’s Verzenio Scores First OS Improvement In Key Breast Cancer Setting In Decades

 
• By Alaric DeArment

The drugmaker announced topline results for the CDK4/6 inhibitor in early HR-positive, HER2-negative breast cancer, giving it a competitive edge over Novartis’s Kisqali.

Psychedelic Drug Development Shows Promise, But Market Path Remains Steep

 
• By Sushmita Panda

With late-stage trials advancing and regulatory guidance in place, psychedelic medicines are nearing a pivotal moment in their path to market. Success will hinge on overcoming clinical, logistical and commercial challenges.

Vor Unveils Positive IgAN Data For Telitacicept, But Prioritizes gMG, Sjögren’s

 
• By Alaric DeArment

A China-only Phase III study for the anti-BAFF/APRIL fusion protein marks the latest positive dataset for the drug, which Vor licensed from China-based RemeGen in June.